Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer (NACSOC-02)
Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement Versus Surgery Alone for Left-Sided Obstructive Colonic Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Jia Gang Han, MD
- Phone Number: +861085231604
- Email: hjg211@163.com
Study Contact Backup
- Name: Zhi Wei Zhai, MD
- Phone Number: +861085231328
- Email: zhaizhiwei@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100020
- Recruiting
- Beijing Chaoyang Hospital, Capital Medical University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Radiologically proven colonic obstruction of the left colon/upper rectum presumed secondary to a carcinoma
- Able to give written, informed consent
- Primary tumor was resectable
- ECOG score 0 or 1
- Haemoglobin greater than 100 g/L after transfusion before chemotherapy,
- White blood cells greater than 3.0×10# /L
- Platelets greater than 100×10# / L;
- Glomerular filtration rate greater than 50 mL per minute as calculated by the Wright or Cockroft formula
- Bilirubin less than 1.5×Upper Limit of Normal(ULN)
- ALT and AST less than 2.5×ULN
Exclusion Criteria:
- Distal rectal cancers(equal or less than 10cm from the anal verge)
- Patients with signs of peritonitis and/or bowel perforation
- Patients who did not give informed consent
- Patients who were considered unfit for operative treatment or refuse surgery.
- Patients with suspected or proven metastatic adenocarcinoma;
- Patients with unresectable colorectal cancer, or planning for palliative treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Immunotherapy group
After clinical success of colonic stenting, regardless of the MSI state all patients will receive Immunotherapy (Camrelizumab 200mg) for 2 cycles compined with neoadjuvant chemotherapy with mFOLFOX6 regimen for 3 cycles or CapeOx regimen for 2 cycles.
Patients will undergo surgery 2-3 weeks after the last cycle of chemotherapy, type and extent of the surgery will be selected by the surgeon.
|
After clinical success of colonic stenting, regardless of the MSI state, patients will receive Immunotherapy (Camrelizumab 200mg) for 2 cycles compined with neoadjuvant chemotherapy with mFOLFOX6 regimen for 3 cycles or CapeOx regimen for 2 cycles.
Patients will undergo surgery 2-3 weeks after the last cycle chemotherapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pathological complete remission
Time Frame: 2 weeks after patients received radical operation
|
No tumor cell found in surgical specimens
|
2 weeks after patients received radical operation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disease Free Survival
Time Frame: 3 years after operation
|
No tumor regrowth or recurrence or metastasis found
|
3 years after operation
|
|
Overall Survival
Time Frame: 3 years after operation
|
Survive during following
|
3 years after operation
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Zhen Jun Wang, MD, Beijing Chao Yang Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2021-12-24
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.